Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention

Front Cover
Gary J. Kelloff, Ernest T. Hawk, Caroline C. Sigman
Springer, Aug 17, 2008 - Medical - 543 pages
0 Reviews
Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development—those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can “reasonably predict” clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

2
39
3
47
4
57
5
69
6
97
Color Plate 1 Fig 2 see discussion in Ch 6
106
Color Plate 4 Fig 2 seefull caption and discussion in
106
7
109
Color Plate 6 Fig 4 see discussion in Ch 29
265
20
268
21
287
22
297
23
305
Bladder Cancer
315
25
325
Endoscopic Detection of Esophageal Neoplasia
343

Fig 2 SAGE Genie Anatomic Viewer display of erbB2 gene
112
8
115
9
123
10
131
11
137
12
141
13
153
14
163
15
185
16
205
17
213
Fig 3 Schematic of the presurgical model of Phase I
223
Fig 4 Schematic of the FNA model for Phase II
225
18
238
Fig 4 Management pathway for incorporating ductal lavage into clinical
243
19
247
27
353
28
371
29
383
Fig 6 Space partitioning of tissue sections for architectural analysis
392
30
403
31
421
32
437
33
449
34
463
35
473
Table 2
478
Strategies for Chemoprevention in Pancreatic Cancer
489
37
503
38
519
Copyright

Other editions - View all

Common terms and phrases

Bibliographic information